Investor Presentation

Jim Green, President and CEO

Mike Rossi, CFO

November 2020

Forward-Looking Statements and Non-GAAP Financial Information

Forward-Looking Statements

The information in this presentation or in oral statements of the management of the Company includes forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. You can identify these statements by our use of such words as "will," "guidance," "objectives," "optimistic," "potential," "future," "expects," "plans," "estimates," "continue," "drive," "strategy," "potential," "potentially," "growth," "long-term," "projects," "projected," "intends," "believes," "goals," "sees," "seek," "develop" "possible" "new," "emerging," "opportunity," "pursue" and similar expressions that do not relate to historical matters. Forward looking statements in this press release or that may be made during our conference call may include, but are not limited to, statements or inferences about the Company's or management's beliefs or expectations, the Company's anticipated future revenues and earnings, the strength of the Company's market position and business model, industry outlook, the impact of the COVID-19 pandemic on the Company's business, the Company's business strategy, the positioning of the Company for growth, the market demand and opportunity for the Company's current products, or products it is developing or intends to develop, and the Company's plans, objectives and intentions that are not historical facts. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Investors should note that many factors, as more fully described under the caption "Risk Factors" in our Form 10-K, including our Form 10-K for the year ended December 31, 2019, and subsequent Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein may cause the Company's actual results to differ materially from those in the forward-looking statements. The forward-looking statements in this press release are qualified by these risk factors. The Company's results may also be affected by factors of which the Company is not currently aware. The Company may not update these forward- looking statements, even though its situation may change in the future, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.

Management's Use of Non-GAAP Financial Information

The information in this presentation or in oral statements of the management of the Company may include non-GAAP financial information including adjusted gross profit, adjusted operating income, adjusted net income and adjusted earnings per diluted share. We believe that this non-GAAP financial information provides investors with an enhanced understanding of the underlying operations of the business. For the periods presented, these non-GAAP financial measures have excluded certain expenses and income primarily resulting from purchase accounting or events that we do not believe are related to the underlying operations of the business such as amortization of intangibles related to acquisitions, costs related to acquisition, disposition and integration activities and stock-based compensation expense. They also exclude the tax impact of the reconciling items. This non-GAAP financial information approximates information used by our management to internally evaluate the operating results of the Company. Any non-GAAP measures included herein are accompanied by a reconciliation to the nearest corresponding GAAP measure within this presentation.

The non-GAAP financial information provided in this presentation should be considered in addition to, not as a substitute for, the financial information provided and presented in accordance with GAAP and may be different than other companies' non-GAAP financial information.

2

Table of Contents

Investment Highlights

Strategic Action Plan

Company Overview

Financial Trends

What We Do

2020 Looking Forward

Evolution of Harvard Bioscience

Experienced Leadership Team

Customer Segments

Appendix

  • Strategic Product Line Investments

3

Investment Highlights

  • Global developer that engineers, manufactures and markets specialized products that enable fundamental research, discovery, and pre-clinical toxicology / safety pharmacology testing for drug development
  • We are the gold standard in Pharma/CRO pre-clinical testing technologies and a respected name in molecular and cell & gene testing and therapy products
  • High margin portfolio of products to Pharma/CRO, Academic Labs, & Distribution/OEM customer segments
  • Seasoned leadership team possesses the right experience and skillsets to drive shareholder value through a focus on business fundamentals
  • Executing the strategic action plan announced in Sept 2019 to transform company into a profitable growth platform
  • Aggressive actions through COVID-19 built a leaner, more profitable business to support our 2021 business targets

4

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Harvard Bioscience Inc. published this content on 18 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 November 2020 12:10:05 UTC